UK approval for Epidyolex to treat seizures from tuberous sclerosis
Approval represents a new indication for GW’s cannabidiol in the UK
Read More
Tag: cannabidiol
GW Pharma’s Epidyolex scores new EU indication
Cannabis-based medicine approved for the treatment of seizures associated with tuberous sclerosis complex
Read More
NICE to work with GW Pharma after Epidiolex rejection
The committee also cited concerns about the economic models provided by the company.
Read More
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
Read More
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
GW’s cannabidiol gets EU orphan status for TS
GW Pharma’s cannabidiol (CBD) has been granted orphan drug designation by European regulators for the treatment of tuberous sclerosis (TS).
Read More
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
Read More
GW’s cannabinoid Epidiolex under EU, US review
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Read More
GW completes Epidiolex submission
GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.
Read More
GW Pharma poised to file Epidiolex in the US
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
Read More
GW’s Epidiolex on track for LGS filing mid-year
GW Pharma’s Epidiolex has impressed again in a late-stage trial involving patients with the rare form of epilepsy Lennox-Gastaut Syndrome (LGS), significantly reducing the number of drop seizures experienced.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
